PROF. DAVID AMES (STUDY LEADER)
The study is lead by Prof. David Ames BA, MD, FRCPsych, FRANZCP, professor of Ageing and Health at the University of Melbourne and Director of The National Ageing Research Institute (NARI). Prof. Ames holds the University of Melbourne’s Foundation Chair of Psychiatry of Old Age at St. George’s Hospital Kew where he is also Director of the Aged Psychiatry Service. He is a member of the Medical & Scientific Advisory Panel of Alzheimer’s Disease International and has been Editor of the Peer Reviewed Journal International Psychogeriatrics since January 2003. His main research interests are new drug treatments for Alzheimer’s disease and the care of the depressed elderly.
DR. ALAN REMBACH (STUDY MANAGER – MELBOURNE)
Dr Alan Rembach is a post-doctoral research scientist and manager of the clinical research group at the Mental Health Research Institute in Parkville, Victoria. Alan received his Bachelor of Science with honours in the Department of Anatomy and Cell Biology at Monash University. He completed a PhD, through the centre for Neuroscience at the University of Melbourne where he graduated in 2006. Alan was awarded a post-doctoral research fellowship at CSIRO in 2007, and began working within the Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging where he is now the site coordinator, aiming to identify individuals at risk for developing Alzheimer’s disease. Principal research interests are focused on peripheral blood based biomarkers for Alzheimer’s disease and other neurodegenerative diseases.
DR. STEPHANIE RAINEY-SMITH (STUDY MANAGER – PERTH)
Stephanie obtained a PhD in Neuroscience from King’s College London, under the supervision of Drs. Robert Williams and Marcus Rattray. Her project investigated TNF modulation of AMPA receptor expression and function in motor neurones and the potential role of this process in the pathogenesis of Motor Neurone Disease. Continuing her work in the area of neurodegenerative diseases, Stephanie joined Professor Ralph Martins’ team in the Centre of Excellence for Alzheimer’s disease Research and Care, based at Edith Cowan University, Western Australia. Stephanie is part of the biomarker team which aims to identify candidate protein biomarkers in order to facilitate the early diagnosis of Alzheimer’s disease, she also co-ordinates the Western Australian arm of the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of ageing.
DR. KATHRYN ELLIS
Dr. Kathryn Ellis BAppSc (Hons), PhD, graduated with a bachelor of applied science with first class honours in psychology and psychophysiology in 2000. She was awarded one of four prestigious Swinburne University Chancellor’s Research Scholarships in 2001 to undertake her PhD in behavioural neurosciences, which involved a year placement at Imperial College of London conducting PET neuroimaging and studies of cognition. Kathryn currently holds a research fellow position at the University of Melbourne and her main roles include national management of the AIBL study and management of the Melbourne node of Dementia Collaborative Research Centre. Dr. Ellis, Prof. Paul Maruff (Chief Science Officer, Cogstate Ltd, and Centre for Neuroscience, University of Melbourne), Associate Prof. Greg Savage (Macquarie Centre for Cognitive Science, NSW) and Dr. Jonathan Foster (Senior Fellow in Cognitive Neuroscience, Edith Cowan University) lead the neuropsychological testing of the cohort to classify participants and monitor their condition.
DR. LANCE MACAULAY
Dr. Lance Macaulay is the Theme Leader of Brain Health in the CSIRO Preventative Health Flagship. Dr. Macaulay is responsible for the strategic development, science planning and project portfolio management of brain health and neurodegenerative disease research activities across the CSIRO Preventative Health Flagship. Dr Macaulay has over 30 years experience in cell biology and biochemistry, specifically signal transduction and metabolic health. His research interests focus on understanding mechanisms that predispose and regulate age onset disease.
PROF. RALPH MARTINS
Prof. Ralph Martins BSC (Hons) PhD holds the Inaugural Chair, Ageing and Alzheimer’s Disease, Edith Cowan University, Western Australia, and also heads the Edith Cowan University’s Centre for Excellence in Alzheimer’s Disease Research and Care. Prof Martins’ research isolated and characterized the protein components of the amyloid deposits characteristic of Alzheimer’s disease. Together with Prof. Ashley Bush (Federation Fellow at the MHRI) who is internationally renowned for seminal discoveries on the impact of metal and oxidative biology on neurodegenerative disorders, Prof. Martins leads the diagnostics and biomarkers program aimed at early stage identification and assessing effectiveness of interventions.
PROF. COLIN MASTERS
Prof. Colin Masters, Emeritus Professor of Pathology, University of Melbourne and Director of The Mental Health Research Institute of Victoria (MHRI) has major input into the biomarkers program based on his discovery of the brain amyloid protein and extensive international network. Prof. Masters is a world leader in research into Alzheimer’s disease and viral infections of the brain. He was the recipient of a 2002 Citation Laureate Award for his contribution to research. He also was awarded Australia’s Mayne Florey Medal in 2002 and the King Faisal Award in 1997. Prof. Masters has held many senior scientific positions and is a Professor of Pathology at the University of Melbourne. He is also Chief of Neuropathology of the Mental Health Research Institute of Victoria, Consultant in pathology at the Royal Melbourne Hospital and a scientific advisor to Neuroscience Australia.
PROF. CHRISTOPHER ROWE
Prof. Christopher Rowe FRACP MD is Director of the Department of Nuclear Medicine and Centre for PET and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Melbourne. He has published extensively on SPECT in epilepsy and beta-amyloid imaging in Alzheimer’s disease. Prof. Rowe and Associate Professor Nat Lenzo (Fremantle Hospital and Edith Cowan University) apply state-of-the-art neuroimaging technology to develop and confirm new diagnostic tests and biomarkers.
Study Team Members
AIBL’s large, multidisciplinary research team includes the following active members.
Chiou Peng Lam
Yen Ying Lim
The following former team members are no longer active in AIBL.